Furthermore, preliminary results from a phase II study of praluzatamab ravtansine (CX-2009), an activated antibody-drug conjugate that targets ALCAM, show promising overall response rate in breast cancer patients with advanced hormone receptor–positive, HER2 negative cancer (57). The gene discussed is ERBB2; the disease is breast carcinoma.